SinghAK, OksM, HuskG, DecharioSP, MinaB, SinghK, et al. Impact of timing of tocilizumab use in hospitalized patients with SARS-CoV-2 infection. Respir Care, 2021; 66(12):1805-1814.
2.
AdilA, SobaniZA, JabbarA, AdilSN, AwanS. Endocrine complications in patients of beta thalassemia major in a tertiary care hospital in Pakistan. J Pak Med Assoc, 2012; 62(3):307-310.
3.
MillerJL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med, 2013; 3(7):a011866-a011866.
4.
JehnM, ClarkJM, GuallarE. Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care, 2004; 27(10):2422-2428.
5.
BrosnahanSB, ChenXJC, ChungJ, AltshulerD, IslamS, ThomasSV, et al. Low-dose tocilizumab with high-dose corticosteroids in patients hospitalized for COVID-19 hypoxic respiratory failure improves mortality without increased infection risk. Ann Pharmacother, 2021:106002802110288. 10600280211028882.
6.
MilicJ, BanchelliF, MeschiariM, FranceschiniE, CiusaG, GozziL, et al. The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. PLoS One, 2021; 16(8):e0251378.
7.
RajaK, DanielN, MorrisonS, PatelR, GergesJ, NadeemK, et al. Impact of tocilizumab on clinical outcomes in COVID-19–associated cytokine release syndrome: a single-center Experience. J Pharm Pract, 20218971900211028208..
